Mast cells squeeze the heart and stretch the gird: Their role in atherosclerosis and obesity

Trends in Pharmacological Sciences

Volumn 32, Issue 9, 2011, Pages 534-542

  Theoharides, Theoharis C ^a,b   Sismanopoulos, Nikolaos ^a,b   Delivanis, Danae Anastasia ^a   Zhang, Bodi ^a   Hatziagelaki, Erifili E ^b   Kalogeromitros, Dimitrios ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; AZELASTINE; C REACTIVE PROTEIN; CARDIONIACIN; CORTICOTROPIN RELEASING FACTOR; CROMOGLYCATE DISODIUM; DESLORATADINE; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; ETANERCEPT; GAMMA INTERFERON; GELATINASE A; HISTAMINE; INTERLEUKIN 1; INTERLEUKIN 6; KETOTIFEN; LOW DENSITY LIPOPROTEIN RECEPTOR; LUTEOLIN; NEUROTENSIN; NICOTINIC ACID; QUERCETIN; REACTIVE OXYGEN METABOLITE; RUPATADINE; SIMVASTATIN; SUBSTANCE P; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ALLERGIC CONJUNCTIVITIS; ALLERGIC DISEASE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BROWN ADIPOSE TISSUE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; FLUSHING; FOOD ALLERGY; HEART MUSCLE NECROSIS; HISTAMINE RELEASE; HUMAN; INSULIN RESISTANCE; MAST CELL; MAST CELL DEGRANULATION; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; SMOOTH MUSCLE FIBER; WHITE ADIPOSE TISSUE;

ANIMALS; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; MAST CELLS; OBESITY; PEPTIDE HYDROLASES;

EID: 80052031318     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2011.05.005     Document Type: Review

References (120)

1. M.A. Beaven Our perception of the mast cell from Paul Ehrlich to now Eur. J. Immunol. 39 2009 11 25
2. M. Rottem, and Y.A. Mekori Mast cells and autoimmunity Autoimmun. Rev. 4 2005 21 27 (Pubitemid 40126368)
3. S.J. Galli The development of allergic inflammation Nature 454 2008 445 454
4. T.C. Theoharides Mast cells and inflammation Biochim. Biophys. Acta 2010 10.1016/j.bbadis.2010.12.014
5. S.N. Abraham, and A.L. St John Mast cell-orchestrated immunity to pathogens Nat. Rev. Immunol. 10 2010 440 452
6. J. Gong The antigen presentation function of bone marrow-derived mast cells is spatiotemporally restricted to a subset expressing high levels of cell surface FcepsilonRI and MHC II BMC Immunol. 11 2010 34
7. E. Crivellato Mast cells and basophils: a potential link in promoting angiogenesis during allergic inflammation Int. Arch. Allergy Immunol. 151 2010 89 97
8. Y. Kitamura, and A. Ito Mast cell-committed progenitors Proc. Natl. Acad. Sci. U.S.A. 102 2005 11129 11130 (Pubitemid 41153786)
9. S. Poglio Adipose tissue as a dedicated reservoir of functional mast cell progenitors Stem Cells 28 2010 2065 2072
10. M.F. Gurish, and J.A. Boyce Mast cells: ontogeny, homing, and recruitment of a unique innate effector cell J. Allergy Clin. Immunol. 117 2006 1285 1291 (Pubitemid 43810217)
11. A.M. Dvorak Mast-cell degranulation in human hearts N. Engl. J. Med. 315 1986 969 970 (Pubitemid 16023690)
12. V. Patella Human heart mast cells: a definitive case of mast cell heterogeneity Int. Arch. Allergy Immunol. 106 1995 386 393
13. P.T. Kovanen Role of mast cells in atherosclerosis Chem. Immunol. 62 1995 132 170
14. Zhang, J. and Shi, G.P. Mast cells and metabolic syndrome. Biochim. Biophys. Acta, 2010 Dec 23. [Epub ahead of print], doi:10.1016/j.bbadis.2010.12. 012
15. R. Ross Atherosclerosis-an inflammatory disease N. Engl. J. Med. 340 1999 115 126
16. G.K. Hansson, and A. Hermansson The immune system in atherosclerosis Nat. Immunol. 12 2011 204 212
17. P. Libby Inflammation and atherosclerosis Circulation 105 2002 1135 1143 (Pubitemid 34212626)
18. M. Suzuki Relation of C-reactive protein and interleukin-6 to culprit coronary artery plaque size in patients with acute myocardial infarction Am. J. Cardiol. 91 2003 331 333 (Pubitemid 36143874)
19. E.N. Deliargyris Sites of interleukin-6 release in patients with acute coronary syndromes and in patients with congestive heart failure Am. J. Cardiol. 86 2000 913 918
20. J.K. Pai Inflammatory markers and the risk of coronary heart disease in men and women N. Engl. J. Med. 351 2004 2599 2610 (Pubitemid 39628581)
21. K. Kandere-Grzybowska Regulation of IL-1-induced selective IL-6 release from human mast cells and inhibition by quercetin Br. J. Pharmacol. 148 2006 208 215 (Pubitemid 43873039)
22. M.B. Forman Increased adventitial mast cells in a patient with coronary spasm N. Engl. J. Med. 313 1985 1138 1141 (Pubitemid 16216831)
23. P. Constantinides Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction Circulation 92 1995 1083 1088
24. M. Kaartinen Mast cells in rupture-prone areas of human coronary atheromas produce and store TNF-a Circulation 94 1996 2787 2792 (Pubitemid 26411742)
25. P. Laine Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery Circulation 99 1999 361 369 (Pubitemid 29051261)
26. N.G. Kounis Coronary stents, hypersensitivity reactions and the Kounis syndrome J. Invasive Cardiol. 20 2007 314 323 (Pubitemid 47429146)
27. D.S. Krantz Effects of mental stress in patients with coronary artery disease: evidence and clinical implications JAMA 283 2000 1800 1802 (Pubitemid 30207601)
28. J. Cao Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor J. Immunol. 174 2005 7665 7675 (Pubitemid 40806271)
29. M. Huang Urocortin induces IL-6 release from rat cardiomyocytes through p38 MAP kinase, ERK and NF-{kappa}B activation J. Mol. Endocrinol. 42 2009 397 405
30. J. Kelley Mast cell activation by lipoproteins Methods Mol. Biol. 315 2006 341 348
31. N.G. Frangogiannis The inflammatory response in myocardial infarction Cardiovasc. Res. 53 2002 31 47 (Pubitemid 34020764)
32. T.C. Theoharides Differential release of mast cell mediators and the pathogenesis of inflammation Immunol. Rev. 217 2007 65 78 (Pubitemid 46718152)
33. A. Lerman Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans Circulation 92 1995 2426 2431
34. M. Reriani Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis Circulation 122 2010 958 966
35. D.B. Murray Endothelin-1 mediates cardiac mast cell degranulation, matrix metalloproteinase activation, and myocardial remodeling in rats Am. J. Physiol. Heart Circ. Physiol. 287 2004 H2295 2299
36. M. Maurer Mast cells promote homeostasis by limiting endothelin-1-induced toxicity Nature 432 2004 512 516 (Pubitemid 39576533)
37. E. Masini Protective effects of M40403, a selective superoxide dismutase mimetic, in myocardial ischaemia and reperfusion injury in vivo Br. J. Pharmacol. 136 2002 905 917 (Pubitemid 34836865)
38. E.J. Swindle, and D.D. Metcalfe The role of reactive oxygen species and nitric oxide in mast cell-dependent inflammatory processes Immunol. Rev. 217 2007 186 205 (Pubitemid 46718146)
39. M. Tagen Mitochondrial uncoupling protein 2 (UCP2) inhibits mast cell activation and reduces histamine content J. Immunol. 183 2009 6313 6319
40. H. Chiao, and R.W. Caldwell The role of substance P in myocardial dysfunction during ischemia and reperfusion Naunyn Schmiedebergs Arch. Pharmacol. 353 1996 400 407 (Pubitemid 26107838)
41. C. Morrey Interaction between sensory C-fibers and cardiac mast cells in ischemia/reperfusion: activation of a local renin-angiotensin system culminating in severe arrhythmic dysfunction J. Pharmacol. Exp. Ther. 335 2010 76 84
42. I. Bot The neuropeptide substance P mediates adventitial mast cell activation and induces intraplaque hemorrhage in advanced atherosclerosis Circ. Res. 106 2010 89 92
43. T.C. Theoharides IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin Proc. Natl. Acad. Sci. U.S.A. 107 2010 4448 4453
44. R. Quirion Selective blockade of neurotensin-induced coronary vessel constriction in perfused rat hearts by a neurotensin analogue Eur. J. Pharmacol. 61 1980 309 312 (Pubitemid 10102467)
45. J. Donelan Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process Proc. Natl. Acad. Sci. U.S.A. 103 2006 7759 7764
46. X. Pang A neurotensin receptor antagonist inhibits acute immobilization stress-induced cardiac mast cell degranulation, a corticotropin-releasing hormone-dependent process J. Pharm. Exp. Ther. 287 1998 307 314 (Pubitemid 29140215)
47. S.A. Zelkha Periodontal innate immune mechanisms relevant to atherosclerosis and obesity Periodontology 2000 54 2010 207 221
48. A.E. Mullick Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events J. Exp. Med. 205 2008 373 383 (Pubitemid 351281603)
49. M. Kulka Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3 J. Allergy Clin. Immunol. 114 2004 174 182 (Pubitemid 39005135)
50. B. Zhang Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis J. Allergy Clin. Immunol. 127 2011 1522 1531
51. M.A. Grimbaldeston Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo Am. J. Pathol. 167 2005 835 848 (Pubitemid 41216366)
52. M. Huang Stress-induced interleukin-6 release in mice is mast cell-dependent and more pronounced in apolipoprotein E knockout mice Cardiovasc. Res. 59 2003 241 249 (Pubitemid 36776390)
53. K. Bhattacharya Mast cell deficient W/Wv mice have lower serum IL-6 and less cardiac tissue necrosis than their normal littermates following myocardial ischemia-reperfusion Int. J. Immunopathol. Pharmacol. 20 2007 69 74 (Pubitemid 46506877)
54. J.R. Gordon, and S.J. Galli Release of both preformed and newly synthesized tumor necrosis factor alpha (TNF-alpha)/cachectin by mouse mast cells stimulated via the Fc epsilon RI. A mechanism for the sustained action of mast cell-derived TNF-alpha during IgE-dependent biological responses J. Exp. Med. 174 1991 103 107
55. N.G. Frangogiannis Resident cardiac mast cells degranulate and release preformed TNF-a, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion Circulation 98 1998 699 710 (Pubitemid 28387497)
56. J. Sun Mast cells promote atherosclerosis by releasing proinflammatory cytokines Nat. Med. 13 2007 719 724 (Pubitemid 46889760)
57. H.M. Heikkila Mast cells promote atherosclerosis by inducing both an atherogenic lipid profile and vascular inflammation J. Cell. Biochem. 109 2010 615 623
58. S. Clejan Blood histamine is associated with coronary artery disease, cardiac events and severity of inflammation and atherosclerosis J. Cell. Mol. Med. 6 2002 583 592 (Pubitemid 44146436)
59. Y. Li Histamine-induced production of interleukin-6 and interleukin-8 by human coronary artery endothelial cells is enhanced by endotoxin and tumor necrosis factor-alpha Microvasc. Res. 61 2001 253 262 (Pubitemid 32976986)
60. C.J. Mackins Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia-reperfusion J. Clin. Invest. 116 2006 1063 1070
61. E. Balcells Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations Am. J. Physiol. 273 1997 H1769 1774
62. D. Baram Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha J. Immunol. 167 2001 4008 4016 (Pubitemid 32910846)
63. M.I. Mayranpaa Desquamation of human coronary artery endothelium by human mast cell proteases: implications for plaque erosion Coron. Artery Dis. 17 2006 611 621 (Pubitemid 44622511)
64. M. Molino Interactions of mast cell tryptase with thrombin receptors and PAR-2 J. Biol. Chem. 272 1997 4043 4049 (Pubitemid 27078466)
65. K. Lotzer Differential leukotriene receptor expression and calcium responses in endothelial cells and macrophages indicate 5-lipoxygenase-dependent circuits of inflammation and atherogenesis Arterioscler. Thromb. Vasc. Biol. 23 2003 e32 36
66. R. Spanbroek Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis Proc. Natl. Acad. Sci. U.S.A. 100 2003 1238 1243 (Pubitemid 36183986)
67. M.F. Gregor, and G.S. Hotamisligil Inflammatory mechanisms in obesity Annu. Rev. Immunol. 29 2011 415 445
68. H. Xu Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance J. Clin. Invest. 112 2003 1821 1830 (Pubitemid 38063705)
69. S.E. Shoelson Inflammation and insulin resistance J. Clin. Invest. 116 2006 1793 1801 (Pubitemid 44033299)
70. G.S. Hotamisligil Inflammation and metabolic disorders Nature 444 2006 860 867 (Pubitemid 46024993)
71. E.D. Rosen, and B.M. Spiegelman Adipocytes as regulators of energy balance and glucose homeostasis Nature 444 2006 847 853 (Pubitemid 46024991)
72. A.M. Cypess Identification and importance of brown adipose tissue in adult humans N. Engl. J. Med. 360 2009 1509 1517
73. H. Tilg, and A.R. Moschen Adipocytokines: mediators linking adipose tissue, inflammation and immunity Nat. Rev. Immunol. 6 2006 772 783 (Pubitemid 44453463)
74. H.W. Koon Neurotensin induces IL-6 secretion in mouse preadipocytes and adipose tissues during 2, 4,6,-trinitrobenzensulphonic acid-induced colitis Proc. Natl. Acad. Sci. U.S.A. 106 2009 8766 8771
75. T.C. Theoharides Allergic inflammation and adipocytokines Int. J. Immunopathol. Pharmacol. 21 2008 1 4 (Pubitemid 351500995)
76. E. Sick Advanced glycation end products (AGEs) activate mast cells Br. J. Pharmacol. 161 2010 442 455
77. S.P. Weisberg Obesity is associated with macrophage accumulation in adipose tissue J. Clin. Invest. 112 2003 1796 1808 (Pubitemid 38063703)
78. M. Feuerer Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters Nat Med. 15 2009 930 939
79. M. Milanski Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: implications for the pathogenesis of obesity J. Neurosci. 29 2009 359 370
80. K. Schroder The NLRP3 inflammasome: a sensor for metabolic danger? Science 327 2010 296 300
81. D.M. Tsukumo Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance Diabetes 56 2007 1986 1998 (Pubitemid 47195825)
82. J. Liu Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice Nat. Med. 15 2009 940 945
83. G.S. Hotamisligil Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance Science 259 1993 87 91 (Pubitemid 23036092)
84. K.T. Uysal Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function Nature 389 1997 610 614 (Pubitemid 27446179)
85. I.S. Farooqi Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency J. Clin. Invest. 110 2002 1093 1103
86. J. Taildeman Human mast cells express leptin and leptin receptors Histochem. Cell Biol. 131 2009 703 711
87. C. Pang Macrophage infiltration into adipose tissue may promote angiogenesis for adipose tissue remodeling in obesity Am. J. Physiol. Endocrinol. Metab. 295 2008 E313 322
88. M.A. Rupnick Adipose tissue mass can be regulated through the vasculature Proc. Natl. Acad. Sci. U.S.A. 99 2002 10730 10735
89. J. Nedvidkova Adiponectin, an adipocyte-derived protein Physiol. Res. 54 2005 133 140 (Pubitemid 40686259)
90. J. Seres Corticotropin-releasing hormone system in human adipose tissue J. Clin. Endocrinol. Metab. 89 2004 965 970 (Pubitemid 38269919)
91. T.C. Theoharides Mast cells as targets of corticotropin-releasing factor and related peptides Trends Pharmacol. Sci. 25 2004 563 568 (Pubitemid 39371146)
92. S. Winer Normalization of obesity-associated insulin resistance through immunotherapy Nat. Med. 15 2009 921 929
93. P. Natarajan, and C.P. Cannon Could direct inhibition of inflammation be the "next big thing" in treating atherosclerosis? Arterioscler. Thromb. Vasc. Biol. 30 2010 2081 2083
94. T.L. Stanley TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome J. Clin. Endocrinol. Metab. 96 2011 E146 150
95. M. Kolak Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes J. Clin. Endocrinol. Metab. 92 2007 720 724
96. P. Peraldi Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling J. Clin. Invest. 100 1997 1863 1869 (Pubitemid 27431346)
97. M.M. Rumore, and K.S. Kim Potential role of salicylates in type 2 diabetes Ann. Pharmacother. 44 2010 1207 1221
98. M.K. Jain, and P.M. Ridker Anti-inflammatory effects of statins: clinical evidence and basic mechanisms Nat. Rev. Drug Discov. 4 2005 977 987
99. Y. Okayama Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine Clin. Exp. Allergy 22 1992 401 409
100. D. Kempuraj Azelastine inhibits secretion of IL-6, TNF-a and IL-8 as well as NF-kB activation and intracellular calcium ion levels in normal human mast cells Int. Arch. Allergy Immunol. 132 2003 231 239 (Pubitemid 37499979)
101. M. Vasiadi Rupatadine inhibits pro-inflammatory mediator secretion from human mast cells triggered by different stimuli Clin. Exp. Allergy 151 2010 38 45
102. 3-receptors: a new frontier in myocardial ischemia J. Pharmacol. Exp. Ther. 292 2000 825 830 (Pubitemid 30136571)
103. S. Takai Targets of chymase inhibitors Expert. Opin. Ther. Targets 15 2011 519 527
104. J.A. Cairns Inhibitors of mast cell tryptase beta as therapeutics for the treatment of asthma and inflammatory disorders Pulm. Pharmacol. Ther. 18 2005 55 66 (Pubitemid 39647754)
105. F. Montecucco New evidence for nicotinic acid treatment to reduce atherosclerosis Expert Rev. Cardiovasc. Ther. 8 2010 1457 1467
106. T.A. Jacobson A "hot" topic in dyslipidemia management - "how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention Mayo Clin. Proc. 85 2010 365 379
107. D. Papaliodis Niacin-induced "flush" involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model J. Pharmacol. Exp. Ther. 327 2008 665 672
108. D. Papaliodis The flavonoid luteolin inhibits niacin-induced flush Br. J. Pharmacol. 153 2008 1382 1387 (Pubitemid 351481506)
109. D. Kalogeromitros A quercetin containing supplement reduces niacin-induced flush in humans Int. J. Immunopathol. Pharmacol. 21 2008 509 514
110. E. Middleton Jr. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer Pharmacol. Rev. 52 2000 673 751
111. D. Kempuraj Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells Br. J. Pharmacol. 145 2005 934 944 (Pubitemid 41129015)
112. M.F. Azevedo Ursolic acid and luteolin-7-glucoside improve lipid profiles and increase liver glycogen content through glycogen synthase kinase-3 Phytother. Res. 24 Suppl. 2 2010 S220 224
113. Z. Deqiu Luteolin inhibits inflammatory response and improves insulin sensitivity in the endothelium Biochimie 93 2011 506 512
114. C. Ando Luteolin, a food-derived flavonoid, suppresses adipocyte-dependent activation of macrophages by inhibiting JNK activation FEBS Lett. 583 2009 3649 3654
115. D. Wootten Modulation of the glucagon-like peptide-1 receptor signaling by naturally occurring and synthetic flavonoids J. Pharmacol. Exp. Ther. 336 2011 540 550
116. AIM-HIGH Investigators The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial Am. Heart J. 161 2011 538 543
117. AIM-HIGH Investigators The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH) Am. Heart J. 161 2011 471-477.e2
118. E. Bruckert, J. Labreuche, and P. Amarenco Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis Atherosclerosis 210 2010 353 361
119. A. Shehadah, J. Chen, A. Zacharek, Y. Cui, M. Ion, C. Roberts, A. Kapke, and M. Chopp Niaspan treatment induces neuroprotection after stroke Neurobiol Dis. 40 2010 277 283
120. J. Chen, X. Cui, A. Zacharek, G.L. Ding, A. Shehadah, Q. Jiang, M. Lu, and M. Chopp Niaspan treatment increases tumor necrosis factor-alpha-converting enzyme and promotes arteriogenesis after stroke J Cereb Blood Flow Metab. 29 2009 911 920